GGrantIndex
← Leaderboards

Timothy R Sterling

Vanderbilt University Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$15,317,436
Attributed
$32,308,791
Total exposure
14
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.1M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$32,308,791 · 14

By mechanism

U01$14,818,694 · 2
R01$14,545,756 · 5
K24$1,590,109 · 1
R56$695,946 · 1
K23$653,400 · 1
M01$4,886 · 4

Top collaborators

Most similar at Vanderbilt University Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Mycobacterium Tuberculosis”

Research focus

Mycobacterium TuberculosisTuberculosisBrazilPersonsInfectionRisk FactorsHiv InfectionsPredispositionPharmaceutical PreparationsClinical ResearchTuberculosis TreatmentIsoniazidCohortFutureFluoroquinolonesReportingGeneticRifampinProspectiveEnrollmentEpidemiologyResearch PersonnelGenesResistance

Grant awards (52)

TB-RICC 3.0$3,925,093
U01 · FY2025 · AI
Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil Network$1,000,000
U01 · FY2025 · AI · contact PI
Pathogen and host predictors of M. tuberculosis transmission$840,116
R01 · FY2025 · AI · contact PI
Pathogen and host predictors of M. tuberculosis transmission$326,817
R01 · FY2025 · AI · contact PI
TB-RICC 3.0$3,960,184
U01 · FY2024 · AI
Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil Network$1,000,000
U01 · FY2024 · AI · contact PI
TB-RICC 3.0$3,933,417
U01 · FY2023 · AI
Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil Network$1,000,000
U01 · FY2023 · AI · contact PI
Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts$750,333
R01 · FY2023 · AI · contact PI
Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts$1,177,109
R01 · FY2022 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$905,202
R01 · FY2021 · AI
Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts$695,679
R01 · FY2021 · AI · contact PI
Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts$972,111
R01 · FY2020 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$929,089
R01 · FY2020 · AI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$884,552
R01 · FY2019 · AI
Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts$726,648
R01 · FY2019 · AI · contact PI
Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis$641,929
R01 · FY2019 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$900,696
R01 · FY2018 · AI
Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis$648,910
R01 · FY2018 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$998,235
R01 · FY2017 · AI
Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis$645,774
R01 · FY2017 · AI · contact PI
Fluoroquinolones and Efflux-Mediated Cross Resistance in HIV-related TB$695,946
R56 · FY2016 · AI · contact PI
Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis$655,701
R01 · FY2016 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$149,982
K24 · FY2014 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$151,218
K24 · FY2013 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$152,446
K24 · FY2012 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$153,673
K24 · FY2011 · AI · contact PI
Fluoroquinolone Resistance in M. Tuberculosis$361,887
R01 · FY2010 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$153,673
K24 · FY2010 · AI · contact PI
Fluoroquinolone Resistance in M. Tuberculosis$365,542
R01 · FY2009 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$167,664
K24 · FY2009 · AI · contact PI
Fluoroquinolone Resistance in M. Tuberculosis$365,542
R01 · FY2008 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$167,664
K24 · FY2008 · AI · contact PI
Fluoroquinolone Resistance in M. Tuberculosis$372,217
R01 · FY2007 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$167,664
K24 · FY2007 · AI · contact PI
Fluoroquinolone Resistance in M. Tuberculosis$381,667
R01 · FY2006 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$164,477
K24 · FY2006 · AI · contact PI
Mentoring in HIV and Tuberculosis Research$161,648
K24 · FY2005 · AI
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$499
M01 · FY2005 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$130,680
K23 · FY2004 · AI
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$4,387
M01 · FY2004 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$120,771
K23 · FY2003 · AI
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$9,909
K23 · FY2003 · AI
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$130,680
K23 · FY2002 · AI
PHARMACOKINETICS OF ISONIAZID/RIFABUTIN--HIV RELATED TB$0
M01 · FY2002 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$0
M01 · FY2002 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$130,680
K23 · FY2001 · AI
PHARMACOKINETICS OF ISONIAZID/RIFABUTIN--HIV RELATED TB$0
M01 · FY2001 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$0
M01 · FY2001 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$130,680
K23 · FY2000 · AI
PHARMACOKINETICS OF ISONIAZID/RIFABUTIN--HIV RELATED TB$0
M01 · FY2000 · RR
RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS$0
M01 · FY2000 · RR